论文部分内容阅读
目的:探讨普拉克索联合美多巴治疗帕金森病的临床效果观察。方法:选取2014年1月至2016年1月来该院治疗的帕金森患者118例,随机分为两组,实验组59例患者采用普拉克索联合美多巴治疗,对照组59例患者则采用美多巴治疗。比较两组患者的临床治疗效果和不良反应发生率。结果:实验组患者治疗总有效率为91.5%,对照组患者治疗的总有效率为81.4%。实验组患者不良反应发生率为11.9%,对照组患者不良反应发生率为22.0%,实验组明显优于对照组(P<0.05)。结论:采用普拉克索联合美多巴治疗帕金森病能够明显改善患者的运动功能,提高临床疗效,并降低并发症的发生,值得临床推广。
Objective: To investigate the clinical effect of pramipexole combined with metopar in the treatment of Parkinson’s disease. Methods: A total of 118 patients with Parkinson’s disease who were treated in our hospital from January 2014 to January 2016 were randomly divided into two groups. 59 patients in the experimental group were treated with pramipexole and metoprolol, while 59 patients in the control group Adoption of Medopa treatment. The clinical efficacy and incidence of adverse reactions in the two groups were compared. Results: The total effective rate was 91.5% in the experimental group and 81.4% in the control group. The incidence of adverse reactions in the experimental group was 11.9%, while the incidence of adverse reactions in the control group was 22.0%. The experimental group was significantly better than the control group (P <0.05). Conclusion: The combination of pramipexole and metopar in the treatment of Parkinson’s disease can significantly improve the patient’s motor function, improve clinical efficacy, and reduce the incidence of complications, worthy of clinical promotion.